The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
|Articles|May 7, 2021
Nexis GC-2030: Excellent Operability and Easy Maintenance
Author(s)Shimadzu Europa
Nexis GC-2030: Excellent operability and easy maintenance
Shimadzu’s next-industry-standard Nexis GC-2030 gas chromatograph (GC) is based on the concept of superior usability and expandability for a wide variety of analytical applications. For these purposes, the
For more information please visit our
Related to this article
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech AI Pulse Check: Fixing AI Slop at the Source
4
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
5